4 percent of those aged 65+ have dementia diagnoses: report
By
Kimberly Bonvissuto
Jun 14, 2024
Four percent of US adults aged 65 or more years have a dementia diagnosis, with rates of dementia increasing with age, according to newly released data.
Senior living can improve dementia care coordination, management for residents as GUIDE program partners
By
Kimberly Bonvissuto
Jun 14, 2024
The nation’s population of older adults — particularly those living with dementia — largely went unnoticed by the population at large for a long time, but the growing numbers of these individuals...
Lifestyle intervention can improve cognition, function in early Alzheimer’s disease
Jun 13, 2024
A significant correlation was seen between lifestyle and both cognitive function and Aβ42/40 ratio.
Residual risk seen for death, postacute sequelae in third year after COVID-19 hospitalization
Jun 13, 2024
The risk for death remains significantly elevated in the third year, as is risk for incident postacute sequelae of COVID-19.
‘Private equity abuse’ in long-term care is target of new federal bill
By
Lois A. Bowers
Jun 13, 2024
Two Democratic senators from Massachusetts have introduced a bill they say is meant to “root out corporate greed and private equity abuse” in nursing homes, assisted living communities, home health...
Systemic side effects of COVID-19 vaccine tied to greater nAB response
Jun 11, 2024
Each 1-degree Celsius increase in skin temperature after a dose was linked to a 1.8- and 3.1-fold higher neutralizing antibody response one and six months later.
The 5-Cog paradigm improves diagnosis, management of dementia
Jun 11, 2024
A threefold improvement was seen in dementia care actions with the 5-Cog paradigm, a culturally adept cognitive detection tool.
Expert panel develops new definition of long COVID
Jun 11, 2024
A new proposed definition for Long COVID could help patients get the help they need, a new report from the National Academies of Sciences, Engineering and Medicine says.
FDA advisers support new Alzheimer’s drug
Jun 11, 2024
A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...
Nirmatrelvir-ritonavir no aid for long COVID symptoms
Jun 10, 2024
The findings based on symptoms at 10 weeks following 15-day course in vaccinated cohort.